We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ManpowerGroup (MAN) Rides on Acquisitions, Debt Woe Persists
Read MoreHide Full Article
ManpowerGroup Inc. (MAN - Free Report) is currently riding on buyouts, strong pricing discipline and cost control, which are benefitting the top line.
The company delivered mixed fourth-quarter 2018 results, with earnings beating the Zacks Consensus Estimate and revenues missing the same. Adjusted EPS of $2.44 outpaced the consensus mark by 24 cents and improved 15.1% on a year-over-year basis. Revenues of $5.39 billion lagged the consensus mark by $152 million and declined 4.3% year over year.
ManpowerGroup has an impressive surprise history. The company beat estimates in three of the trailing four quarters, the average being 4.4%. For the first quarter of 2019, the consensus mark declined 5.6% in the past 30 days.
What’s Driving ManpowerGroup?
The company is currently benefiting from a strong staffing industry, leading to robust manufacturing and non-manufacturing activities as well as higher corporate spending post the tax reform. While the economy continues to create new jobs despite a low jobless rate, a tight labor market is compelling companies to pay higher to attract and retain employees. There are ample opportunities for ManpowerGroup to grow in the United States in the near to mid-term as the demand environment for staffing services is strong.
ManpowerGroup is trying to mitigate the ongoing revenue softness through strong pricing discipline and cost control methods. It continues to witness solid growth in the solutions business, especially in MSP and RPO solutions. In a bid to increase productivity and efficiency, the company is making significant investments in technology. It is implementing front office systems, cloud-based and mobile applications.
ManpowerGroup is consistently acquiring and investing in companies on a global basis to strengthen its diverse portfolio. Buyouts continue to support the company’s top line. Acquisitions contributed 20 basis points (bps) to fourth-quarter 2018 revenue growth rate.
Southern Europe, the company’s largest reportable segment (43% of 2018 revenues), is likely to continue to experience staffing margin pressure stemming from competitiveness and employment (CICE) rate decline in France. The rate fall from 7% to 6% of eligible wages will be effective with payroll paid initiated from Jan 1, 2018.
Also, ManpowerGroup has a debt-laden balance sheet that may limit future expansion and worsen risk profile. As of Dec 31, 2018, long-term debt was $1.03 billion, while cash and cash equivalents were $591.9 million.
A few better-ranked stocks in the Zacks Business Services sector are Insperity, Inc. (NSP - Free Report) , Information Services Group, Inc. (III - Free Report) and Everi Holdings Inc. (EVRI - Free Report) . While Insperity sports a Zacks Rank #1, Information Services Group and Everi Holdings carry a Zacks Rank #2 (Buy).
The long-term expected EPS (three to five years) growth rate for Insperity, Information Services Group and Everi Holdings is 18%, 14% and 20%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
ManpowerGroup (MAN) Rides on Acquisitions, Debt Woe Persists
ManpowerGroup Inc. (MAN - Free Report) is currently riding on buyouts, strong pricing discipline and cost control, which are benefitting the top line.
The company delivered mixed fourth-quarter 2018 results, with earnings beating the Zacks Consensus Estimate and revenues missing the same. Adjusted EPS of $2.44 outpaced the consensus mark by 24 cents and improved 15.1% on a year-over-year basis. Revenues of $5.39 billion lagged the consensus mark by $152 million and declined 4.3% year over year.
ManpowerGroup has an impressive surprise history. The company beat estimates in three of the trailing four quarters, the average being 4.4%. For the first quarter of 2019, the consensus mark declined 5.6% in the past 30 days.
What’s Driving ManpowerGroup?
The company is currently benefiting from a strong staffing industry, leading to robust manufacturing and non-manufacturing activities as well as higher corporate spending post the tax reform. While the economy continues to create new jobs despite a low jobless rate, a tight labor market is compelling companies to pay higher to attract and retain employees. There are ample opportunities for ManpowerGroup to grow in the United States in the near to mid-term as the demand environment for staffing services is strong.
ManpowerGroup is trying to mitigate the ongoing revenue softness through strong pricing discipline and cost control methods. It continues to witness solid growth in the solutions business, especially in MSP and RPO solutions. In a bid to increase productivity and efficiency, the company is making significant investments in technology. It is implementing front office systems, cloud-based and mobile applications.
ManpowerGroup is consistently acquiring and investing in companies on a global basis to strengthen its diverse portfolio. Buyouts continue to support the company’s top line. Acquisitions contributed 20 basis points (bps) to fourth-quarter 2018 revenue growth rate.
ManpowerGroup Inc. Price
ManpowerGroup Inc. Price | ManpowerGroup Inc. Quote
Risks
Southern Europe, the company’s largest reportable segment (43% of 2018 revenues), is likely to continue to experience staffing margin pressure stemming from competitiveness and employment (CICE) rate decline in France. The rate fall from 7% to 6% of eligible wages will be effective with payroll paid initiated from Jan 1, 2018.
Also, ManpowerGroup has a debt-laden balance sheet that may limit future expansion and worsen risk profile. As of Dec 31, 2018, long-term debt was $1.03 billion, while cash and cash equivalents were $591.9 million.
Zacks Rank & Stocks to Consider
Currently, ManpowerGroup carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A few better-ranked stocks in the Zacks Business Services sector are Insperity, Inc. (NSP - Free Report) , Information Services Group, Inc. (III - Free Report) and Everi Holdings Inc. (EVRI - Free Report) . While Insperity sports a Zacks Rank #1, Information Services Group and Everi Holdings carry a Zacks Rank #2 (Buy).
The long-term expected EPS (three to five years) growth rate for Insperity, Information Services Group and Everi Holdings is 18%, 14% and 20%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>